Parkin antibody (C-Term)

Catalog No. ABIN350726

The Rabbit Polyclonal anti-Parkin antibody has been validated for WB and IHC. It is suitable to detect Parkin in samples from Mouse and Rat.

Quick Overview for Parkin antibody (C-Term) (ABIN350726)

Target: Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))

Reactivity: Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Parkin antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Product Details anti-Parkin Antibody

Binding Specificity: C-Term

Purpose: Rabbit antibody to Parkin

Specificity: Specific for Parkin.

Cross-Reactivity: Human, Mouse, Rat

Cross-Reactivity (Details): Other species not yet tested.

Purification: IgG

Immunogen: A synthetic peptide from the c-terminal of Parkin (PARK2 Parkinson disease protein 2) conjugated to an immunogenic carrier protein was used as the immunogen. The antigen is homologous in rat and shares 95% identity with mouse sequence.

Isotype: IgG

Application Details

Application Notes: IHC WB. A concentration of 10-50,micro,g,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Reconstitute in 500 µl of sterile water. Centrifuge to remove any insoluble material.

Handling Advice: Avoid freeze and thaw cycles.

Storage: 4 °C,-20 °C

Storage Comment: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Expiry Date: 12 months

Target Details for Parkin

Target: Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))

Alternative Name: Parkin

Background: Function: Functions within a multiprotein E3 ubiquitin ligase complex catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11 CCNE1 GPR37 STUB1 a 22 kDa O-linked glycosylated isoform of SNCAIP and SEPT5. May play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity proteasomal dysfunction GPR37 accumulation and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin E during neuronal apoptosis. May represent a tumor suppressor gene. Subcellular location: Cytoplasm. Nucleus. Note: Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. Tissue specificity: Highly expressed in the brain including the substantia nigra. Expressed in heart testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis.

Pathways: Autophagy, Ubiquitin Proteasome Pathway